Search research articles
Contact Us
Filters
Showing results (111-120 of 129) with videos related to
Page
of 13
Sort By:
International Journal of Oncology
|
November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review
William K Oh, David McDermott, Camillo Porta, et al.
Ebiomedicine
|
August 25, 2022
Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma
Niccolò Rossi, Karla A Lee, Maria V Bermudez, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2022
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Nature Communications
|
July 2, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years
Claus Garbe, Ulrike Keim, Teresa Amaral, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 21, 2023
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023
Ketty Peris, Maria Concetta Fargnoli, Roland Kaufmann, et al.
The New England Journal of Medicine
|
October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Jessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
BMC Cancer
|
February 22, 2023
Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma
Alessia Visconti, Niccolò Rossi, Helena Deriš, et al.
The New England Journal of Medicine
|
October 22, 2025
Nivolumab for Resected Stage III or IV Melanoma at 9 Years
Paolo A Ascierto, Michele Del Vecchio, Barbara Merelli, et al.
Lancet (London, England)
|
June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 19, 2024
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 129) with videos related to
Sort By:
Page
of 13
International Journal of Oncology
|
November 20, 2013
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review
William K Oh, David McDermott, Camillo Porta, et al.
Ebiomedicine
|
August 25, 2022
Circulating inflammatory proteins associate with response to immune checkpoint inhibition therapy in patients with advanced melanoma
Niccolò Rossi, Karla A Lee, Maria V Bermudez, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 15, 2022
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Nature Communications
|
July 2, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years
Claus Garbe, Ulrike Keim, Teresa Amaral, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 21, 2023
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023
Ketty Peris, Maria Concetta Fargnoli, Roland Kaufmann, et al.
The New England Journal of Medicine
|
October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal Melanoma
Jessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
BMC Cancer
|
February 22, 2023
Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma
Alessia Visconti, Niccolò Rossi, Helena Deriš, et al.
The New England Journal of Medicine
|
October 22, 2025
Nivolumab for Resected Stage III or IV Melanoma at 9 Years
Paolo A Ascierto, Michele Del Vecchio, Barbara Merelli, et al.
Lancet (London, England)
|
June 4, 2015
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina V Long, Daniil Stroyakovskiy, Helen Gogas, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 19, 2024
European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024
Claus Garbe, Teresa Amaral, Ketty Peris, et al.
Page
of 13